Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer
Release date: 02-02-2024
Expiration date: 02-02-2025
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including patient selection for cisplatin/carboplatin eligible and platinum ineligible and optimal treatment strategy in the first-line setting, sequencing of treatments and the management of treatment-related adverse events. An improved understanding of the role and application of immunotherapy, chemotherapy, antibody-drug conjugates (ADC) and targeted treatments to routine patient care will facilitate optimal management of patients with urothelial cancer.
This program is available with subtitles in the following languages:
Faculty
Shilpa Gupta, MD
Taussig Cancer Institute
Cleveland Clinic
Cleveland, USA
Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. She is also a Clinical Professor of Medicine at the Lerner College of Medicine at Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta leads several early and late-phase clinical trials in Genitourinary Cancers and has several leadership roles in NCI trials including overall study chair for the MAINCAV trial of maintenance avelumab and cabozantinib in urothelial cancer. She is Principal Investigator of a Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and serves on the scientific advisory and steering committee for the Bladder cancer Advocacy Network (BCAN).
Enrique Grande, MD, MSc, PhD | Chair
MD Anderson Cancer Center Madrid
Madrid, Spain
Enrique Grande is the current Director of the Medical Oncology Program at the MD Anderson Cancer Center Madrid. Dr. Grande is focused on the research into genitourinary tumors and is actively involved in collaborating on the development of the Translational Research and Early Drug Development Unit. Dr. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Center (CNIO). A published author of more than 200 manuscripts in peer-reviewed journals, Dr. Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Dr. Grande is the editor of several international journals and has been the editor of a range of books related to oncology. Dr. Grande has participated in the most recent trials in the field of genitourinary and neuroendocrine tumors that led to the approval of the new drugs we now have available.
Yohann Loriot, MD, PhD
Institute Gustave Roussy
University of Paris-Saclay
Villejuif, France
Yohann Loriot was appointed as Senior Lecturer and Consultant in Medical Oncology at Gustave Roussy, Villejuif, France, in 2013. He works in clinical drug development within genitourinary trials and has a particular interest in rationally designed molecular targeted therapies and immunotherapies in urothelial and bladder cancer. Dr Loriot graduated from the University of Paris in 2009 and completed a PhD in 2014. He was awarded a travelling scholarship and pursued further research at the Vancouver Prostate Cancer Centre in Vancouver, Canada. Dr Loriot received the prestigious ASCO Conquer Foundation Young Investigator Award in 2014. Over the last 5 years, Dr Loriot has been involved in the development of multiple novel agents, many of which are now approved drugs, and he is currently running over 20 clinical trials. Dr Loriot is currently a member of the steering committees of multiple international clinical trials from phase I to phase III, and a co-author of collaborative work, published in N Engl J Med, Nature, Lancet Oncology, European Urology, and J Clin Oncol. He has been involved in trials leading to several drug approvals (enzalutamide, abiraterone, atezolizumab, erdafitinib). Dr Loriot’s major research focus involves the study of molecular mechanisms mediating progression to lethal disease in bladder and prostate cancer and the use of this information to develop novel new strategies and therapies.
Thomas Powles, MD, MRCP, MBBS
Barts Cancer Centre
St Bartholomew's Hospital
London, UK
Thomas Powles is Professor of Genitourinary Oncology and Director of Barts Cancer Centre in London, UK. He trained in medical oncology at Imperial College London, UK, and completed his post-graduate training in oncology in 2005, receiving an MD from the University of London in 2006, with a thesis on the mechanisms of resistance to therapy in urological cancers. Prof. Powles is the lead for solid tumor research at Barts Cancer Institute, London, leading a spectrum of clinical trials across phase I–III, including biomarker, novel targeted, and immune therapies studies. He is the author of over 300 peer-reviewed publications in all the major medical journals. Prof. Powles participates in, or leads, a number of guidelines committees.
The proposed initiative is specifically designed for medical oncologists, urologists, and other healthcare professionals involved or interested in the management of urothelial cancer, with the focus of Europe and APAC.
Upon completion of this educational activity, participants should be able to:
- Establish confidence and expertise in the selection of first-line treatment throughout defining the criteria of cisplatin eligible, carboplatin eligible and platinum ineligible in unresectable locally advanced or metastatic urothelial cancer
- Transfer knowledge into practice and utilize maintenance immunotherapy in the most optimum way in first-line setting to extend survival of patients with unresectable locally advanced or metastatic urothelial cancer
- Develop strategies for the prevention and management of adverse events associated with the range of treatments used in unresectable locally advanced or metastatic urothelial cancers
- Identify how to sequence available treatments for second-line or later-line of unresectable locally advanced or metastatic urothelial cancers
- Improve understanding of the novel drugs in development and consider the impact to optimize the new treatment strategies in the future
This educational activity is provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
The Faculty of Pharmaceutical Medicine has approved this event for continuing professional development (CPD) and allocated it 1,25 CPD credits.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Shilpa Gupta has served as an advisor or consultant for Merck, EMD Sorono, BMS, Bayer, Gilead Sciences, Foundation Medicine, Astellas, Seattle Genetics and Genzyme. She has also served as a speaker or a member of a speakers bureau for Seattle Genetics, Gilead and BMS. She has received grants for clinical research from BMS, Merck, Novartis, Exelixis, Genetech, Acrivon Therapeutics and Seattle Genetics. Dr Gupta owns stock, stock options, or bonds from Nektar Therapeutics, BionTech and Moderna. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Enrique Grande has received honoraria for speaker engagements, advisory roles or funding for continuing medical education from Advanced Accelerator Applications, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, Genetracer, GSK, Guardant Health, HRAPharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Raffo, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific and Zodiac. He has also received grants for clinical research from Astellas, Astra Zeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold/Tersera, Nanostring Technologies, Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Yohann Loriot has served as an advisor or consultant for MSD, Astra Zeneca, BMS, Roche, Merck KGaA, Pfizer, Seattle Genetics, Gilead, Tahio, Astellas and Janssen. He has received grants for clinical research from MSD, Roche, Sanofi, Janssen and Celsius. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Thomas Powles has served as an advisor or consultant for AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche. He has received grants for clinical research from AstraZeneca, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche. He has also provided strategic advisory for AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson and Eisai. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.